MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration
Kelly Wallace Stinson(Pharmaceutical Product Development (United States)), Lawrence Geiter(Pharmaceutical Product Development (United States)), Juliano Timm, Barry N. Kreiswirth(Center for Discovery), Masanori Kawasaki(Otsuka (Japan)), Mamoru Fujiwara(Otsuka (Japan)), Makoto Matsumoto(Tottori University Hospital), Natalia Kurepina(Rutgers, The State University of New Jersey), Yongge Liu(Pharmaceutical Product Development (United States)), Amour Venter(Stellenbosch University), Elena Shashkina(Rutgers, The State University of New Jersey)
Cited by 57
Related Papers
A Toll-like receptor recognizes bacterial DNA
|Nature|2000|6.4k
HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY
|The Lancet|1986|2.4k
Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
|Immunity|1998|2k
Essential role of Stat6 in IL-4 signalling
|Nature|1996|1.6k
Community-associated meticillin-resistant Staphylococcus aureus
|The Lancet|2010|1.5k